Skip to content

ACT Capital Partners, L.P. 13F Holdings · Q3 2026

ACT Capital Partners, L.P. reported 58 securities worth $153.96M in its SEC 13F filing for Q3 2026 (period ended 2026-09-30). Top holdings: CVX (9.95%), KRYS (9.07%), TGTX (8.59%). Among its top 25 positions this quarter: 24 new.

RankTickerCompanyValue% PortfolioSharesAction
1CVXCHEVRON CORPORATION$15.3M9.95%75,000New
2KRYSKRYSTAL BIOTECH INC$14.0M9.07%42,000New
3TGTXTG THERAPEUTICS INC$13.2M8.59%237,200New
4XOMEXXONMOBIL HOLDINGS CORP$12.8M8.30%78,500New
5AMZNAMAZON COM INC$10.6M6.88%42,500New
6ABVXABIVAX SA$8.4M5.47%85,000New
7VKTXVIKING THERAPEUTICS INC$7.2M4.66%220,200New
8SKHYSK HYNIX INC$6.4M4.15%34,700New
9ARWRARROWHEAD PHARMACEUTICALS IN$6.2M4.00%94,000New
10NKTRNEKTAR THERAPEUTICS$5.5M3.55%90,400New
11TSLATESLA INC$5.3M3.41%14,800New
12CELCCELCUITY INC$4.7M3.03%58,650New
13MUMICRON TECHNOLOGY INC$3.7M2.42%3,500New
14NUVBNUVATION BIO INC$3.2M2.11%579,500New
15PVLAPALVELLA THERAPEUTICS INC NE$3.1M2.02%22,500New
16ETENERGY TRANSFER L P$2.6M1.71%133,100New
17BEBLOOM ENERGY CORP$2.5M1.62%9,000New
18ASTSAST SPACEMOBILE INC$2.3M1.49%39,000New
19FCXFREEPORT MCMORAN INC$2.3M1.48%32,500New
20CCJCAMECO CORP$2.2M1.43%25,400New
21MLYSMINERALYS THERAPEUTICS INC$2.2M1.43%87,400New
22AXTIAXT INC$2.0M1.27%25,200New
23HELPCYBIN INC$1.7M1.08%135,000New
24CADLCANDEL THERAPEUTICS INC$1.6M1.02%150,500New
25HXSCLSK HYNIX INC$1.3M0.84%7,000 (underlying)Call

Source: SEC Form 13F filings · as of 2026-09-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR